A Study of LY3473329 in Participants With Impaired and Normal Renal Function
Renal Insufficiency
About this trial
This is an interventional basic science trial for Renal Insufficiency
Eligibility Criteria
Inclusion Criteria: Have a body mass index within the range 19.0 to 42.0 kilograms per meter squared (kg/m²) Men who agree to use highly effective or effective methods of contraception, women of childbearing potential (WOCP) who agree to use highly effective or effective methods of contraception, and women not of childbearing potential (WNOCBP) may participate in this trial Have clinical laboratory test results within the normal reference range for the population Exclusion Criteria: Have a history or presence of an underlying disease, or surgical, physical, medical, or psychiatric condition that, in the opinion of the investigator, would potentially affect participant safety within the study Have any abnormality in the 12-lead electrocardiogram (ECG), blood pressure and/or pulse rate that, in the opinion of the investigator, increases the risks associated with participating in the study Hemoglobin less than 8 grams/deciliter (g/dL) and/or clinically significant anemia symptoms Have an average weekly alcohol intake that exceeds 21 units per week for males and 14 units per week for females or males older than 65 years of age Smoke more than 10 cigarettes per day or the equivalent Have donated blood of more than 500 milliliter (mL) within 3 months prior to screening
Sites / Locations
- Velocity Clinical ResearchRecruiting
- Advanced Pharma CR, LLCRecruiting
- Orlando Clinical Research CenterRecruiting
- Alliance for Multispecialty Research - Clinical Research ConsortiumRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Experimental
Experimental
Experimental
Experimental
Experimental
LY3473329 (Control)
LY3473329 (Mild Renal Impairment)
LY3473329 (Moderate Renal Impairment)
LY3473329 (Severe Renal Impairment)
LY3473329 (End-Stage Renal Disease)
LY3473329 administered orally to participants with normal renal function
LY3473329 administered orally to participants with mild renal impairment
LY3473329 administered orally to participants with moderate renal impairment
LY3473329 administered orally to participants with severe renal impairment
LY3473329 administered orally to participants with end-stage renal disease